Chongqing Zhifei Biological Products Co.,Ltd.
Chongqing Zhifei Biological Products Co.,Ltd. is a Chinese biotechnology company founded in 2002 and listed on the ChiNext board of the Shenzhen Stock Exchange.
Last updated October 12, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Chongqing Zhifei Biological Products Co.,Ltd., known as Zhifei Biological, is a Chinese biotechnology company. According to its official website, it was founded in 2002 and describes itself as an internationalized, full-industry-chain high-tech biopharmaceutical enterprise integrating R&D, production, sales, distribution and import/export. Its stated mission is to prevent disease and treat existing illness while safeguarding human health, and its stated vision is to become a world-class biopharmaceutical enterprise. The company reports three major R&D and production bases and two innovation incubation centers, with 41 pipeline projects across seven product matrices, 5 in-licensed/agency products and 10 self-developed products on sale. It was listed on the ChiNext board of the Shenzhen Stock Exchange in 2010.
History
According to the development history published on its official website, Zhifei Biological was founded in 2002 and formally entered the biopharmaceutical industry. In 2003 it established its first R&D and production base, Beijing Zhifei Lvzhu. In 2008 it acquired and established Anhui Zhifei Longcom, building its second major R&D and production base. In 2010 it was listed on the ChiNext board of the Shenzhen Stock Exchange. In 2011 it reached a strategic cooperation with Merck (MSD). In 2014 it took an equity stake in Chongqing Zhirui Investment Co., Ltd., extending into the broader biopharmaceutical field. In 2017 it began acting as agent for an imported quadrivalent human papillomavirus vaccine, and in 2018 for an imported nonavalent human papillomavirus vaccine. In 2023 it reached a strategic cooperation with GSK. In 2025 it increased capital to take a controlling stake in Chongqing Chenan Biological, extending its business into the metabolic disease field.
- 2025
Increased capital to take a controlling stake in Chongqing Chenan Biotech, extending its business into the metabolic disease field.
- 2023
Entered into a strategic partnership with GSK.
- 2018
Began distributing the imported nonavalent (9-valent) HPV vaccine.
- 2017
Began distributing the imported quadrivalent human papillomavirus (HPV) vaccine.
- 2014
Took an equity stake in Chongqing Zhirui Investment Co., Ltd., expanding into the broader biopharmaceutical field.
- 2011
Entered into a strategic partnership with Merck (MSD).
- 2010
Listed on the ChiNext board of the Shenzhen Stock Exchange.
- 2008
Acquired and established Anhui Zhifei Longcom, building its second major R&D and production base.
- 2003
Established its first R&D and production base, Beijing Zhifei Lvzhu.
- 2002
Chongqing Zhifei Biological Products was founded and formally entered the biopharmaceutical industry.
Products and positioning
An international high-tech biopharmaceutical company with a full industry chain; committed to becoming a world-class biopharmaceutical enterprise
盟威克® [ACYW135群脑膜炎球菌多糖疫苗]
喜菲贝® [b型流感嗜血杆菌结合疫苗]
优威克® [23价肺炎球菌多糖疫苗]
微卡® [注射用母牛分枝杆菌]
宜卡® [重组结核杆菌融合蛋白(EC)]
流感病毒裂解疫苗
达舒宸® [利拉鲁肽注射液]
盟纳康® [A群C群脑膜炎球菌多糖结合疫苗]
盟纳克® [A群C群脑膜炎球菌多糖疫苗]
[四价流感病毒裂解疫苗]
智克威得® [重组新型冠状病毒蛋白疫苗(CHO细胞)]
Controversies
Sources8 sources
Cite this profile: Cite the canonical profile. /brand-wiki/chongqing-zhifei-biological-products-coltd · Editorial policy · How profiles are compiled